Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver

An erythritol, non-alcoholic technology, applied in the field of application of erythritol in the preparation of drugs for the treatment of non-alcoholic fatty liver, can solve the problems of no research and reports on the therapeutic effect

Inactive Publication Date: 2021-04-20
JILIN UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no studies and reports on the therapeuti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver
  • Application of erythritol in preparation of medicine for treating non-alcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 AML12 Cell Oil Red O Staining Experiment

[0033] experimental method:

[0034] (1) AML12 cells were cultured and seeded in six-well plates. The formula of cell culture medium is F12 medium with 4.5g / L glucose, 10% fetal calf serum, 1% penicillin and streptomycin, 1% ITS, 40ng / ml dexamethasone (Sigma, D4902-100mg). Cells were cultured in 5% CO 2 and in a cell culture incubator at 37°C for 12 hours.

[0035] (2) Remove the original culture medium and replace it with F12 with only 4.5g / L glucose as the culture medium to culture the cells, and starve the AML12 cells for 3 hours.

[0036] (3) AML12 cells were co-incubated with 250 mg / ml erythritol and 1000 μM free fatty acid (oleic acid:palmitic acid=2:1) ​​for 24 hours; among them, they were divided into blank group (F12 medium), model group (1000 μM free fatty acid ), control group (250mg / ml erythritol), experimental group (250mg / ml erythritol+1000μM free fatty acid).

[0037] (4) The cell culture medium wa...

experiment example 2W

[0044] Experimental example 2Western blot detection of lipid regulatory protein expression in HEPG2 cells

[0045] experimental method

[0046] (1) Culture HEPG2 cells and inoculate them in a six-well plate with a density of 1×10 per well 6 cells. The formula of the cell culture medium is DMEM medium with 4.5g / L glucose, 10% fetal bovine serum and 1% penicillin and streptomycin. Cells were cultured in 5% CO 2 and in a cell culture incubator at 37°C for 12 hours.

[0047] (2) Remove the original culture medium and replace it with DMEM with only 4.5g / L glucose as the culture medium to culture the cells, and starve the HEPG2 cells for 3 hours.

[0048] (3) Co-incubate HEPG2 cells with 250 mg / ml erythritol and 1000 μM free fatty acid (oleic acid:palmitic acid=2:1) ​​for 24 hours; wherein, they are divided into blank group (DMEM medium), model group (1000 μM free fatty acid ), control group (250mg / ml erythritol), experimental group (250mg / ml erythritol+1000μM free fatty acid)....

Embodiment 3

[0058] Determination of TG in the mouse liver of embodiment 3

[0059] experimental method:

[0060] (1) Raise the mice in an SPF environment with a temperature of 24±1° C. and a relative humidity of 40%-80%.

[0061] (2) Before the experiment, the mice were separated into cages and fasted for 12 hours, and then injected intraperitoneally with 50 mg / kg, 100 mg / kg, and 200 mg / kg of erythritol for 1 hour and then injected with 500 mg / kg of tyloxapol Mice were injected intraperitoneally for 12 hours. The mice were randomly divided into seven groups: blank group (normal saline), model group (500mg / kg tyloxapol), control group (200mg / kg erythritol), drug low dose group (50mg / kg erythritol sugar alcohol+500mg / kg tyloxapol), drug middle dose group (100mg / kg erythritol+500mg / kg tyloxapol), drug high dose group (200mg / kg erythritol+500mg / kg Tyloxapol), drug positive control group (100mg / kg fenofibrate+500mg / kg Tyloxapol).

[0062] (3) The mouse liver was completely removed and cut ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of erythritol in preparation of a medicine for treating non-alcoholic fatty liver. Pharmacological experiments show that the erythritol has a good treatment effect on a non-alcoholic fatty liver mouse model and a hepatocyte lipid accumulation model. Experimental results prove that the erythritol can effectively reduce the lipid content in hepatocytes by regulating expression of acetyl-coenzyme A carboxylase (ACC) and cholesterol regulatory element binding protein 1c (SREBP-1c) in hepatocytes; In mice with non-alcoholic fatty liver, the erythritol can significantly reduce lipid accumulation in the liver and can significantly inhibit the levels of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase. In a word, the erythritol can play a role in regulating the blood fat by inhibiting the expression of SREBP-1 and ACC.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of erythritol in the preparation of medicines for treating non-alcoholic fatty liver. Background technique [0002] Non-alcoholic fatty liver (NAFLD) is a series of syndromes caused by liver parenchymal cell degeneration and fat accumulation caused by non-alcoholic effects. According to whether the lesion tissue is accompanied by inflammation and fibrosis, it can be divided into simple fatty liver , steatohepatitis and its associated cirrhosis and hepatocellular carcinoma. Non-alcoholic fatty liver is divided into two types: primary and secondary. The primary type is related to insulin resistance and genetics, and the secondary type is related to obesity, diabetes, hyperlipidemia, and the environment. [0003] At present, the existing drugs for the treatment of NAFLD mainly include: ①Insulin enhancers: rosiglitazone and pioglitazone, which are thiazolidinediones, can r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/047A61P1/16
Inventor 冯海华张迪韦云飞金美玉严斯如覃海燕王齐王建锋邱家章
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap